For the second time this year, a major pharmaceutical wholesaler has reached agreement with a coalition of institutional investors to bolster oversight of opioid distribution and board accountability.

In this instance, the Cardinal Health (CAH) board agreed to create a committee to monitor the risks of distributing the addictive painkillers and provide investors with reports of two investigations into allegations of failed oversight. In addition, the wholesaler agreed to post detailed information about its policies and efforts on its website.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy